Educational Activities Archives

According to the Substance Abuse and Mental Health Services Administration, in 2019, only 10% of adults in the U.S with any substance use disorder (SUD) received treatment in part because effective evidence-based treatments for SUDs can be difficult to access in many communities.  CCBHCs help address this issue, delivering easily accessible and effective outpatient behavioral health care and SUD treatment through activities including expanded operating hours, same-day and walk-in appointments, outreach to sidelined populations and moving service delivery beyond clinic walls to reach people in their homes and in the community.

Over 2.5 million adults in the U.S. are diagnosed with OUD. In 2022, 12.7% of ED visits involved opioids. Yet only 25% of those who need treatment receive recommended MOUD. MOUDs are highly effective treatments that have been shown to decrease opioid use, cravings and transmission of infectious disease, and to increase retention in treatment. As the opioid epidemic continues to impact people across the U.S., the ED represents a critical access point to the health care system, supporting people with OUD by initiating MOUD, such as buprenorphine, and connecting them to low-threshold, easy-to-access care for continued treatment.

This webinar describes the evidence and regulations for methadone in emergency rooms and hospitals, including protocols for rapid methadone initiation and applying changes to the 3-day rule.

This session explores the clinical and policy landscape of providing medications for opioid use disorder (MOUD) in jails, prisons, and reentry settings. Dr. Arthur Robin Williams and Dr. Peter Treitler review recent research on the effectiveness of MOUD in reducing overdose and improving post-release treatment engagement. The session highlights key differences among methadone, buprenorphine, and extended-release naltrexone, including regulatory and logistical considerations unique to correctional environments. Learners will examine policy updates, case-based examples, and implementation strategies that support evidence-based treatment access. The session also addresses interdisciplinary collaboration, diversion concerns, and continuity of care across incarceration and reentry.

This educational activity, presented by Dr. Phillip Coffin, explores the evolving landscape of methamphetamine use amidst the growing presence of fentanyl. Attendees will gain insights into current morbidity and mortality trends, the physiological mechanisms behind methamphetamine toxicity, and evidence-based interventions for managing methamphetamine use disorder (MeUD). Emphasis will be placed on comprehensive prevention, treatment strategies, and addressing the long-term cardiovascular and neuropsychiatric impacts associated with chronic use.

Participants who engage in this activity will understand opioid pharmacology and evidence on benefits and harms of opioid therapy for chronic pain. Additionally, participants learn risk factors for opioid overdose and OUD, risk assessment of patients for long-term opioid therapy, methods for mitigating risks of opioid therapy, and approaches for discontinuing or tapering opioids.